hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06356077 id: OBPM_HTN2024 briefTitle: Evaluation of the Satisfaction of a Hypertensive Population in Their Use of the Aktiia 24/7 Blood Pressure Monitor acronym: OBPM_HTN2024 overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-12 date: 2027-12 date: 2024-04-10 date: 2024-04-10 name: Aktiia SA class: INDUSTRY briefSummary: OBPM_HTN2024 study was designed by AKTIIA SA to evaluate how a hypertensive population, reflective of the United States and encompassing a range of phenotypes, perceives the Aktiia 24/7 device (Aktiia G1) during their first 3 months of use. conditions: Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 5000 type: ESTIMATED measure: Preferences of subjects regarding the method to monitor their blood pressure between Aktiia Bracelet, Home Blood Pressure Monitor, or Ambulatory Blood Pressure Monitor measure: Frequency of Aktiia app use measure: Frequency of use of Aktiia device as compared to previously use other blood pressure monitors measure: Evaluation of subject's experience in using the Aktiia App measure: Evaluation of the most valuable data on the Aktiia Mobile App by subjects sex: ALL minimumAge: 21 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06356064 id: E2-23-3834 briefTitle: Radial or Focus Extracorporeal Shock Wave Therapy in Epin Calcanei overallStatus: COMPLETED date: 2023-05-15 date: 2023-12-15 date: 2024-01-15 date: 2024-04-10 date: 2024-04-22 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Objective: The aim of the study was to investigate the effectiveness of radial and focused ESWT treatment on pain, function, and size of the calcaneal spur in patients with a clinical and radiological diagnosis of epin calcanei.
Methods: A total of 112 patients aged between 18 and 95 years were randomly divided into two groups: group 1 received rESWT (2.4 bar 12 hz 2000 beats), and group 2 received fESWT (0.14 bar 14 hz 1000 beats) three times a week for three weeks. All patients were evaluated using the Visual Analog Scale (VAS)-pain and Foot Function Index (FFI) before and after the treatment, at 4 weeks and 12 weeks. Epin size was measured radiographically in the patients before and after the treatment at the 12-week follow-up. conditions: Spur, Heel studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 112 type: ACTUAL name: Extracorporeal shock wave therapy measure: Visual Analog Scale measure: Functional Foot Index measure: Radiographic assesment, epin size sex: ALL minimumAge: 18 Years maximumAge: 95 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Özge TEZEN city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06356051 id: Gbuyukyilmaz briefTitle: Cardiovascular Disease Risk in Children With Type 1 Diabetes Mellitus overallStatus: COMPLETED date: 2023-01-01 date: 2023-06-01 date: 2023-09-01 date: 2024-04-10 date: 2024-04-10 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Epicardial fat thickness, carotid intima-media thickness, and augmentation index from arterial stiffness indicators are increased in children with T1DM compared to the healthy control group. These results support the idea that children with T1DM present significant changes in important subclinical indicators for the development of cardiovascular disease. conditions: Type 1 Diabetes studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 202 type: ACTUAL name: Echocardiography measure: Epicardial fat thickness measure: carotid intima-media thickness measure: arterial stiffness parameters such as pulse wave velocity, augmentation index sex: ALL minimumAge: 8 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Ankara Bilkent City Hospital city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-01-04 uploadDate: 2024-03-30T05:04 filename: Prot_SAP_000.pdf size: 347934 hasResults: False
nctId: NCT06356038 id: Prot. n. 76 SA/2022 briefTitle: Phrenic Nerve Infiltration: Pulmonary Expansion and Pain Control overallStatus: ACTIVE_NOT_RECRUITING date: 2022-03-09 date: 2025-01-02 date: 2025-01-02 date: 2024-04-10 date: 2024-04-10 name: Azienda Ospedaliera "Sant'Andrea" class: OTHER briefSummary: Between January 2021-2023, 65 consecutive patients at risk for PAL (defined in accordance to "2019 Society of Thoracic Surgery score-criteria of PAL") underwent lung resection (lobectomy or sublobar resection) for malignancy. 5 patients were lost. The remaining have been assigned with a 1:2 randomization into: group A (22 patients), received intra-operative phrenic nerve infiltration with Ropivacaine 10 mg/ml in the peri-neurotic fat on the pericardium and group B (38 patients), did not receive infiltration. Data on hemidiaphragm elevation, air leaks, pain at 24 and 72 hours post-surgery, shoulder pain, length of hospital stay, length of chest tube permanence, were retrospectively collected and compared.The aim of the study is to investigate the effect of intra-operative phrenic nerve infiltration with long acting anesthetic in patients at high risk for PAL, improving pulmonary expansion after surgery, and reducing air leaks, while controlling post-operative pain. conditions: Prolonged Air Leak conditions: Post-operative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 66 type: ACTUAL name: intra-operative phrenic nerve infiltration measure: rate of pulmonary expansion due by phrenic nerve intra-operative local anaesthetic infiltration measure: rate of post-operative pain control after intra-operative phrenic nerve infiltration with local anaesthetic sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliera "Sant'Andrea" city: Roma country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06356025 id: 52082 id: 2024-512546-42 type: EUDRACT_NUMBER briefTitle: Botulinum Toxin Injection in the UES for R-CPD acronym: BOTUS R-CPD overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-07 date: 2027-07 date: 2024-04-10 date: 2024-04-10 name: AZ Delta class: OTHER name: KU Leuven briefSummary: The aim of this study is to assess the effect of botulinum toxin injection into the upper esophageal sphincter in a double blind, placebo controlled study. Investigators want to assess the effect on symptoms short term (1-20 weeks after BT injection), and long term (48 weeks after BT injection).
This is a prospective double-blind randomized placebo-controlled study. Questionnaires assessing symptoms will be filled out on several occasions. At 20 weeks, a reassessment of symptoms will be done, without unblinding patients or investigator. Failures (to BT or placebo, defined as no clinical improvement or improvement less than 50%) will get the chance to receive a second procedure with active treatment (BT) in open label. conditions: Retrograde Cricopharyngeus Dysfunction studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: botulinum toxin type A name: Sodium Chloride 0.9% Inj measure: Change of at least 50% of 'inability to belch' using the symptom questionnaire at week 12. measure: Change in associated gastrointestinal symptoms: abdominal bloating/discomfort measure: Change in associated gastrointestinal symptoms: abdominal/chest pain measure: Change in associated gastrointestinal symptoms: flatulence measure: Change in associated gastrointestinal symptoms: gurgling noises from the chest/lower neck measure: Change of at least 50% of 'inability to belch' during long term follow-up at week 20, and at 48 weeks. measure: Overall treatment effect (OTE) measure: Overall symptom severity (OSS) measure: EuroQol-5D (EQ-5D) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06356012 id: 71163523.1.0000.5437 briefTitle: Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2026-12-31 date: 2028-12-31 date: 2024-04-10 date: 2024-04-10 name: Barretos Cancer Hospital class: OTHER name: Fundação de Amparo à Pesquisa do Estado de São Paulo name: Farmoquimica S.A. name: Hospital de Cancer de Barretos - Fundacao Pio XII briefSummary: The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients. conditions: HSIL, High-Grade Squamous Intraepithelial Lesions conditions: Vaginal Microbiome conditions: Biomarkers studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 96 type: ESTIMATED name: Imiquimod name: Loop Electrosurgical Excision Procedure measure: Number of participants with histological regression of High-grade squamous intraepithelial lesion (HSIL) measure: Identification of immune response in vaginal and plasma collection measure: Correlation between vaginal microbiome and immunological response sex: FEMALE minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06355999 id: 2007p000646-F briefTitle: Levari Exp.20: 2D - Partial Feedback overallStatus: COMPLETED date: 2021-05-01 date: 2021-06-01 date: 2021-06-01 date: 2024-04-10 date: 2024-04-10 name: Brigham and Women's Hospital class: OTHER briefSummary: Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormality and by the feedback that observers (Os) receive. If abnormal spots are rare (low prevalence), Os will tend to become more conservative about calling spots abnormal. In this experiment, Os see items defined by color and shape. They are looking for one combination (bumpy green). Bumpy green targets can be common (50% prevalence) or rare (10%). Os in one group will get feedback about their responses based on color. The other group will receive feedback based on shape. The investigators will look for effects of prevalence and of the type of feedback. The goal is to better understand perceptual decisions in settings like clinical evaluation of skin lesions. conditions: Form Perception conditions: Color Perception conditions: Decision Making studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups, each receiving different feedback primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Observers are naive as to the purpose of the experiment until after participation whoMasked: PARTICIPANT count: 55 type: ACTUAL name: Feedback measure: Participant naming of visual stimuli sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Visual Attention Lab / Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06355973 id: 2024-01-061 briefTitle: A Pilot Study for Efficacy of Cognitive and Physical Training in Patients With Mild Cognitive Impairment overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12-31 date: 2024-12-31 date: 2024-04-10 date: 2024-04-10 name: MinYoung Kim, MD, PhD class: OTHER briefSummary: This is to find out the effectiveness of cognitive and physical function training for patients with mild cognitive impairment.
It is for the prevention and treatment of dementia in the future. randomized, Pilot Study. conditions: Patients With Mild Cognitive Impairment (MCI) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Using tablets and workbooks cognitive function. name: self-programming of physical function training. measure: Montreal Cognitive Assessment (MoCA) measure: Korean-Mini Mental Status Examination (K-MMSE) measure: Clinical Dementia Rating (CDR) measure: Clinical Global Impressions of Change (CGIC) measure: Instrumental Activities of Daily Living (I-ADL) measure: Berg Balance Scale (BBS) measure: Geriatric Quality of Life-Dementia (GQOL-D) measure: Geriatric Depression Scale (GDSd) measure: Global Deterioration Scale (GDS) measure: Electroencephalography sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355960 id: 2024-853 briefTitle: Effect of Dexmedetomidine on Oxygenation and Lung Mechanics overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-04-10 date: 2024-04-10 name: Cairo University class: OTHER briefSummary: Dexmedetomidine is a selective α -2 agonist widely used in anesthesia for its sympatholytic, sedative and analgesic effects . Favorable respiratory effects in animals , and in selected human patient groups have been reported when using this agent .we investigated the effects of different doses of dexmedetomidine infusion on oxygenation conditions: Drug Use conditions: Dexmedetomidine studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 176 type: ESTIMATED name: GROUP Dexmedetomidine name: GROUP B name: GROUP C measure: Oxygenation by the end study measure: Intraoperative dynamic lung compliance measure: Intraoperative static lung compliance measure: Physiological dead space sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo university city: Cairo zip: 11562 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06355947 id: 103-7445B briefTitle: Cycling and Treadmill With Dual Task for Parkinson's Disease Improvement overallStatus: COMPLETED date: 2015-12-07 date: 2017-09-11 date: 2018-07-31 date: 2024-04-10 date: 2024-04-10 name: Chang Gung University class: OTHER briefSummary: Motor impairment in lower extremities is common in individuals with Parkinson disease (PD). Development sensitive test for early motor deviations is important. Conventional walking test cannot induce the PD related motor impairments, such as freezing of gait. Therefore, finding a safe substitute test to induce PD related motor impairments is important.
The purpose of the third year is to evaluate the effect of 8 week long term cycling training or treadmill training of individuals with PD on motor cortex plasticity, dual task performance, and ambulation ability. conditions: Parkinson Disease(PD) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ACTUAL name: Cognitive cycling training name: Cognitive treadmill training measure: Walking Speed measure: Step Length measure: Step Time measure: Power Spectral Density (PSD) measure: Task Accuracy measure: Reaction Time measure: Balance Performance measure: Double Support Time measure: Single Support Time measure: Swing Time measure: Stance Time measure: Cadence measure: Heart rate sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung University city: Taoyuan zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06355934 id: D8450R00004 briefTitle: OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis acronym: OverTTuRe overallStatus: RECRUITING date: 2023-08-21 date: 2026-09-30 date: 2026-09-30 date: 2024-04-10 date: 2024-04-29 name: AstraZeneca class: INDUSTRY briefSummary: The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented. conditions: ATTR Amyloidosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 55000 type: ESTIMATED name: no intervention measure: Health Care Resource Utilization (HCRU) - Outpatient visits measure: Health Care Resource Utilization (HCRU) - Outpatient visits by specialty measure: Health Care Resource Utilization (HCRU) - Emergency department visits measure: Health Care Resource Utilization (HCRU) - Hospitalizations, length of stay measure: Health Care Resource Utilization (HCRU) - Hospitalizations measure: Health Care Resource Utilization (HCRU) - Health care cost measure: Cardiac transplant measure: All cause mortality measure: Liver transplant measure: Heart Failure Hospitalization measure: New ATTR amyloidosis clinical manifestation measure: Hospitalization (any cause) measure: Neuropathy Impairment Score (NIS) measure: Neuropathy Impairment Score Lower Limbs (NIS-LL) measure: Neuropathy Impairment Score +7 (NIS+7) measure: Neuropathy Impairment Score modified +7 (mNIS+7) measure: Neuropathy symptoms and change (NCS) score measure: PND (Polyneuropathy Disability) measure: Other relevant clinical measurement of ATTR amyloidosis functional status measure: Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QoL-DN) Score measure: Health Care Resource Utilization (HCRU) - Outpatient visits measure: Health Care Resource Utilization (HCRU) - Outpatient visits by specialty measure: Health Care Resource Utilization (HCRU) - Emergency department visits measure: Health Care Resource Utilization (HCRU) - Hospitalizations, length of stay measure: Health Care Resource Utilization (HCRU) - Hospitalizations measure: Health Care Resource Utilization (HCRU) - Health care cost sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: COMPLETED city: Eden Prairie state: Minnesota zip: 55344 country: United States lat: 44.85469 lon: -93.47079 facility: Research Site status: RECRUITING city: Horsens country: Denmark lat: 55.86066 lon: 9.85034 facility: Research Site status: COMPLETED city: Tokyo country: Japan lat: 35.6895 lon: 139.69171 facility: Research Site status: RECRUITING city: London country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06355921 id: RFAdesmoid briefTitle: A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors acronym: RFAdesmoid overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-02-01 date: 2028-05-01 date: 2024-04-10 date: 2024-04-10 name: Blokhin's Russian Cancer Research Center class: OTHER briefSummary: This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors.
In the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months. conditions: Desmoid Tumor conditions: Desmoid Fibromatosis conditions: Desmoid studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: radiofrequency ablation measure: Comparison of safety assessment. measure: Overall Response Rate measure: Duration of responce measure: Comparison of tumor necrosis based on MRI/CT sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO) city: Moscow state: MO zip: 115522 country: Russian Federation name: Artem Galustov role: CONTACT phone: 9169117818 email: artem115583@mail.ru name: Aslan Valiev, PhD role: PRINCIPAL_INVESTIGATOR name: Denis Sofronov, PhD role: SUB_INVESTIGATOR lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06355908 id: TT002 briefTitle: IL13Rα2 CAR-T for Patients With r/r Glioma acronym: ENHANCING overallStatus: RECRUITING date: 2024-03-21 date: 2026-05-01 date: 2027-05-01 date: 2024-04-10 date: 2024-04-10 name: Yang Zhang class: OTHER name: TCRCure Biopharma Ltd. briefSummary: This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma. conditions: Glioma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: IL13Rα2 CAR-T measure: Safety of IL13Rα2 CAR-T measure: Overall Response Rate (ORR) measure: Duration of Response (DOR) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Overall Survival (OS) at 6 months (OS6) measure: Overall Survival (OS) at 12 months (OS12) measure: The levels of IL13Rα2 CAR-T cell and IL13Rα2 CAR in the CSF and peripheral blood measure: The levels of cytokines in the CSF and peripheral blood measure: The Exploratory Indicators sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tiantan Hospital status: RECRUITING city: Beijing country: China name: Yang Zhang, MD, phD role: CONTACT phone: +861059976516 email: zhangyang8025@yeah.net lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06355895 id: HCC 23-104 briefTitle: Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-10 date: 2024-04-10 name: University of Pittsburgh class: OTHER name: American College of Radiation Oncology briefSummary: Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and fast-fed variations in liver volume affect treatment planning for abdominal SBRT. conditions: Upper Abdominal Malignancies studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 17 type: ESTIMATED name: Standardized high-carbohydrate meal measure: Diurnal Difference in Liver Volumes measure: Difference in total liver volume measure: Percentage diurnal difference in liver mean dose at V5 Gy measure: Percentage diurnal difference in liver mean dose at V15Gy measure: Difference in liver mean dose at V15 Gy measure: Difference in liver dose at V15 Gy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UPMC Hillman Cancer Center city: Pittsburgh state: Pennsylvania zip: 15232 country: United States name: Samantha Demko role: CONTACT name: Brieanna Marino role: CONTACT name: Susannah Ellsworth, MD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False